Effect of blood sample type on the measurement of advanced oxidation protein products as a biomarker of inflammation and oxidative stress in hemodialysis patients

被引：14

作者：

Chen, Yuan-Han ^{[1
]}

Shi, Wei ^{[1
]}

Liang, Xin-Ling ^{[1
]}

Liang, Yong-Zheng ^{[1
]}

Fu, Xia ^{[1
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Acad Med Sci, Div Nephrol, Guangzhou 510080, Guangdong, Peoples R China

来源：

BIOMARKERS | 2011年 / 16卷 / 02期

关键词：

Advanced oxidation protein products; biomarker; cardiovascular disease; hemodialysis; sample preparation; ACUTE-PHASE RESPONSE; CARDIOVASCULAR-DISEASE; FIBRINOGEN FRAGMENTS; ADVANCED GLYCATION; KIDNEY-DISEASE; UREMIC PLASMA; RENAL-DISEASE; MYELOPEROXIDASE; ATHEROSCLEROSIS; MARKER;

D O I：

10.3109/1354750X.2010.535172

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Advanced oxidation protein products (AOPP) is widely used as a uremic biomarker, especially for cardiovascular disease. However, it has not been determined whether it is better to measure AOPP in plasma or serum. In this cross-sectional study, which included 102 patients undergoing maintenance hemodialysis, fibrinogen-free serum and defibrinated plasma samples were prepared. AOPP levels from fibrinogen-free samples displayed a stronger correlation with myeloperoxidase activity and levels of C-reactive protein, interleukin-6 and tumor necrosis factor-alpha, as well as prevalent cardiovascular disease, than AOPP levels obtained from plasma samples. These results demonstrated that fibrinogen interferes with the measurement of AOPP.</.

引用

页码：129 / 135

页数：7

共 40 条

[1] Evaluation of some biochemical changes in diabetic patients [J].

Abou-Seif, MA ;

Youssef, AA .

CLINICA CHIMICA ACTA, 2004, 346 (02) :161-170

[2] Principal component analysis of some oxidative stress parameters and their relationships in hemodialytic and transplanted patients [J].

Antolini, F ;

Valente, F ;

Ricciardi, D ;

Baroni, M ;

Fagugli, RM .

CLINICA CHIMICA ACTA, 2005, 358 (1-2) :87-94

[3] Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis [J].

Baskol, Gulden ;

Demir, Huseyin ;

Baskol, Mevlut ;

Kilic, Eser ;

Ates, Filiz ;

Karakukcu, Cigdem ;

Ustdal, Muzaffer .

CELL BIOCHEMISTRY AND FUNCTION, 2006, 24 (04) :307-311

[4] Advanced oxidation protein products -: A novel marker of oxidative stress in ulcerative colitis [J].

Baskol, Mevlut ;

Baskol, Gulden ;

Kocer, Derya ;

Ozbakir, Omer ;

Yucesoy, Mehmet .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (06) :687-691

[5]

BRADLEY PP, 1982, BLOOD, V60, P618

[6] Biochemical and spectrophotometric significance of advanced oxidized protein products [J].

Capeillère-Blandin, C ;

Gausson, V ;

Descamps-Latscha, B ;

Witko-Sarsat, V .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2004, 1689 (02) :91-102

[7] Respective role of uraemic toxins and myeloperoxidase in the uraemic state [J].

Capeillere-Blandin, Chantal ;

Gausson, Valerie ;

Nguyen, Anh Thu ;

Descamps-Latscha, Beatrice ;

Drueke, Tilman ;

Witko-Sarsat, Veronique .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (06) :1555-1563

[8]

Descamps-Latscha A, 2005, AM J KIDNEY DIS, V45, P39, DOI 10.1053/j.ajkd.2004.09.011

[9]

DING F, 2006, J NEPHROL, V22, P33

[10] Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease [J].

Drüeke, T ;

Witko-Sarsat, V ;

Massy, Z ;

Descamps-Latscha, B ;

Guerin, AP ;

Marchais, SJ ;

Gausson, V ;

London, GM .

CIRCULATION, 2002, 106 (17) :2212-2217

← 1 2 3 4 →